Le produit a bien été ajouté au panier.

discount label
H-ELAGIGILTV^-OH
Vue en 3D

Biosynth logo

H-ELAGIGILTV^-OH

Ref. 3D-PP47742

Taille indéfinieÀ demander
Livraison estimée en/au États-Unis, le mardi 10 décembre 2024

Informations sur le produit

Nom :
H-ELAGIGILTV^-OH
Description :

Peptide H-ELAGIGILTV^-OH is a Research Peptide with significant interest within the field academic and medical research. This peptide is available for purchase at Cymit Quimica in multiple sizes and with a specification of your choice. Recent citations using H-ELAGIGILTV^-OH include the following: Rational design of peptide-based tumor vaccines WS Meng , LH Butterfield - Pharmaceutical research, 2002 - Springerhttps://link.springer.com/article/10.1023/A:1016497818471 Peptide super-agonist enhances T-cell responses to melanoma SAE Galloway, G Dolton , M Attaf, A Wall - Frontiers in , 2019 - frontiersin.orghttps://www.frontiersin.org/articles/10.3389/fimmu.2019.00319/full Cutting edge: predetermined avidity of human CD8 T cells expanded on calibrated MHC/anti-CD28-coated microspheres S Walter, L Herrgen, O Schoor, G Jung - The Journal of , 2003 - journals.aai.orghttps://journals.aai.org/jimmunol/article/171/10/4974/1858 Altered peptide ligands revisited: Vaccine design through chemically modified HLA-A2-restricted T cell epitopes R Hoppes, R Oostvogels , JJ Luimstra - The Journal of , 2014 - journals.aai.orghttps://journals.aai.org/jimmunol/article/193/10/4803/97379 Modification of MHC Anchor PTATCR Binding, RG Heteroclitic - J. Immunol, 2010 - Citeseerhttps://citeseerx.ist.psu.edu/document?repid=rep1&type=pdf&doi=cf719cdb0be3af6be38c9b96c3dfdbb892f3435c From peptides to small molecules: an intriguing but intricated way to new drugs PL Scognamiglio, C Di Natale - Current medicinal , 2013 - ingentaconnect.comhttps://www.ingentaconnect.com/content/ben/cmc/2013/00000020/00000031/art00001 Crystal structures of two closely related but antigenically distinct HLA-A2/melanocyte-melanoma tumor-antigen peptide complexes P Sliz , O Michielin, JC Cerottini, I Luescher - The Journal of , 2001 - journals.aai.orghttps://journals.aai.org/jimmunol/article/167/6/3276/33980 Convergence of the specificity and cross-reactivity of multiple T cell receptors isolated against a single cancer peptide/HLA complex P Sharma , DT Harris, MV Hager, DM Kranz - Cancer Research, 2018 - AACRhttps://aacrjournals.org/cancerres/article-abstract/78/13_Supplement/3581/627815 Fluorescence labeling of anchor-modified Mart-1 peptide for increasing its affinity for HLA-A* 0201: Hit two targets with one arrow P Fattahi, N Salehi , Z Azizi - Journal of Peptide , 2023 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1002/psc.3480 CD8 T cell function and cross-reactivity explored by stepwise increased peptide-HLA versus TCR affinity P Baumgaertner, J Schmidt, CM Costa-Nunes - Frontiers in , 2022 - frontiersin.orghttps://www.frontiersin.org/articles/10.3389/fimmu.2022.973986/full Synthesis of Glycocluster-Tumor Antigenic Peptide Conjugates for Dendritic Cell Targeting O Srinivas, P Larrieu, E Duverger - Bioconjugate , 2007 - ACS Publicationshttps://pubs.acs.org/doi/abs/10.1021/bc070026g Melan-A/MART1 analog peptide triggers anti-myeloma T-cells through crossreactivity with HM1. 24 O Christensen, A Lupu, S Schmidt - Journal of , 2009 - journals.lww.comhttps://journals.lww.com/immunotherapy-journal/fulltext/2009/07000/Recognition_of_Shared_Melanoma_Antigens_in.8.aspx Immunogenic decapeptide in melanoma immunotherapy NK Mishra, AK Sharma , TK Mukherjee - Journal of molecular modeling, 2016 - Springerhttps://link.springer.com/article/10.1007/s00894-016-3140-8 MHC Class I Molecules with NA CTLs, SCD Binding - J. Immunol, 2010 - Citeseerhttps://citeseerx.ist.psu.edu/document?repid=rep1&type=pdf&doi=f8202eb4619e178604accb92076d32557c5daa64 Adoptive T cell therapy using antigen-specific CD8+ T cells for the treatment of patients with metastatic melanoma: a phase I clinical study N Meidenbauer, S Vogl, M Laumer, J Heymann - Cancer Cell , 2004 - Springerhttps://link.springer.com/article/10.1186/1475-2867-4-S1-S10 Improved detection of melanoma antigen-specific T cells expressing low or high levels of CD8 by HLA-A2 tetramers presenting a Melan-A/Mart-1 peptide analogue MJ Maeurer , A Necker, RD Salter - journal of cancer, 2002 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1002/ijc.1580 Synthesis and Biological Evaluation of Hapten-Clicked Analogues of The Antigenic Peptide Melan-A/MART-126(27L)-35 M Tarbe, JJ Miles , ESJ Edwards , KM Miles - , 2020 - Wiley Online Libraryhttps://chemistry-europe.onlinelibrary.wiley.com/doi/abs/10.1002/cmdc.202000038 Soluble HLA-I/peptide monomers mediate antigen-specific CD8 T cell activation through passive peptide exchange with cell-bound HLA-I molecules M Allard , R Oger, H Benlalam, L Florenceau - The Journal of , 2014 - journals.aai.orghttps://journals.aai.org/jimmunol/article/192/11/5090/92443 Peptide mimic for influenza vaccination using nonnatural combinatorial chemistry JJ Miles , MP Tan, G Dolton - The Journal of , 2018 - Am Soc Clin Investighttps://www.jci.org/articles/view/91512 Detection of antigen-specific T-cells with MHC/peptide-tetramer-complexes G Tully, E Jager, MJ Maeurer - Clinical and Applied Immunology Reviews, 2002 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S1529104902000569 MHC-peptide-specific antibodies reveal inefficient presentation of an HLA-A* 0201-restricted, Melan-A-derived peptide after active intracellular processing G Held, A Wadle, N Dauth - European journal of , 2007 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1002/eji.200636545 Crystallization and preliminary X-ray structural studies of a Melan-A pMHC-TCR complex F Yuan, T Georgiou, T Hillon, E Gostick - Section F: Structural , 2007 - scripts.iucr.orghttps://scripts.iucr.org/cgi-bin/paper?pu5196 TCR-induced alteration of primary MHC peptide anchor residue F Madura, PJ Rizkallah , M Legut - European journal of , 2019 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1002/eji.201948085 Impact of antigen presentation on TCR modulation and cytokine release: implications for detection and sorting of antigen-specific CD8+ T cells using HLA-A2 wild-type E Jäger, R Salter, C Castelli, H Höhn - The Journal of , 2002 - journals.aai.orghttps://journals.aai.org/jimmunol/article/168/6/2766/34711 Impact of antigen presentation on TCR modulation and cytokine release: implications for detection and sorting of antigen-specific CD8 T cells using HLA-A2 E Jager, R Salter, C Castelli, H Höhn, K Freitag - J. Immunol, 2002 - academia.eduhttps://www.academia.edu/download/47681918/Impact_of_antigen_presentation_on_TCR_mo20160731-32057-yvft53.pdf Peptide-specific CD8+ T-cell evolution in vivo: Response to peptide vaccination with Melan-A/MART-1 E Jager, H Höhn, A Necker, R Förster - journal of cancer, 2002 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1002/ijc.10165 Modification of MHC anchor residues generates heteroclitic peptides that alter TCR binding and T cell recognition DK Cole , ESJ Edwards , KK Wynn - The Journal of , 2010 - journals.aai.orghttps://journals.aai.org/jimmunol/article/185/4/2600/103229 Diversity of the fine specificity displayed by HLA-A* 0201-restricted CTL specific for the immunodominant Melan-A/MART-1 antigenic peptide D Valmori, N Gervois, D Rimoldi - The Journal of , 1998 - journals.aai.orghttps://journals.aai.org/jimmunol/article/161/12/6956/1064 Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues D Valmori, JF Fonteneau , CM Lizana - The Journal of , 1998 - journals.aai.orghttps://journals.aai.org/jimmunol/article/160/4/1750/905 Covalent modification of a melanoma-derived antigenic peptide with a natural quinone methide. Preliminary chemical, molecular modelling and immunological C Douat-Casassus, N Marchand-Geneste - Molecular , 2006 - pubs.rsc.orghttps://pubs.rsc.org/en/content/articlehtml/2006/mb/b518044a Synthetic anticancer vaccine candidates: rational design of antigenic peptide mimetics that activate tumor-specific T-cells C Douat-Casassus, N Marchand-Geneste - Journal of medicinal , 2007 - ACS Publicationshttps://pubs.acs.org/doi/abs/10.1021/jm0613368 Survival and Tumor Localization of A Mackensen , S Vogl, J Heymann, R Andreesen - J , 2003 - researchgate.nethttps://www.researchgate.net/profile/Joerg-Marienhagen/publication/10912107_Survival_and_Tumor_Localization_of_Adoptively_Transferred_Melan-A-Specific_T_Cells_in_Melanoma_Patients/links/568ba9a008ae051f9afc55e7/Survival-and-Tumor-Localization-of-Adoptively-Transferred-Melan-A-Specific-T-Cells-in-Melanoma-Patients.pdf Stability and CTL activity of N-terminal glutamic acid containing peptides A Beck , MC Bussat, C Klinguer-Hamour - Journal of Peptide , 2001 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1034/j.1399-3011.2001.00895.x Peptides as tools and drugs for immunotherapies A Beck , C Klinguer-Hamour, MC Bussat - Journal of Peptide , 2007 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1002/psc.852 Peptide-based strategies for targeted tumor treatment and imaging A Ayo, P Laakkonen - Pharmaceutics, 2021 - mdpi.comhttps://www.mdpi.com/1999-4923/13/4/481

Avis:
Nos produits sont destinés uniquement à un usage en laboratoire. Pour tout autre usage, veuillez nous contacter.
Marque:
Biosynth
Stockage à long terme :
Notes :

Propriétés chimiques

MDL:
Point de fusion :
Point d'ébullition :
Point d'éclair :
Densité :
Concentration :
EINECS :
Merck :
Code SH :

Informations sur les risques

Numéro ONU :
EQ:
Classe :
Phrases R :
Phrases S :
Transport aérien interdit :
Informations sur les risques :
Groupe d'emballage :
LQ :

Question d’ordre technique sur : 3D-PP47742 H-ELAGIGILTV^-OH

Veuillez plutôt utiliser le panier afin de demander un devis ou passer commande

Si vous souhaitez demander un devis ou passer commande, veuillez plutôt ajouter les produits souhaités à votre panier, puis demander un devis ou passer commande à partir de votre panier. C'est une méthode plus rapide, plus économique, et vous pourrez bénéficier des remises disponibles ainsi que d'autres avantages

* Champ obligatoire
Bienvenue chez CymitQuimica !Nous utilisons des cookies pour améliorer votre visite. Nous n’incluons pas de publicité.

Veuillez consulter notre Politique de Cookies pour plus de détails ou ajustez vos préférences dans "Configurer".